Tigercat Pharma, Inc., is a largely 'virtual' company created to hold the ownership of the VPD-737 development program. Tigercat is funded by Velocity Pharmaceutical Holdings, and Remeditex Ventures. The VPD-737 development program is managed under contract by VPD. VPD is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/19/13 | undisclosed |
Remeditex Ventures | undisclosed |
